Generic Medicine Info
Indications and Dosage
Acne vulgaris
Adult: As 1% cream/gel: Apply to affected area bid. Discontinue treatment if desired effect is not achieved after 4 weeks.
Hypersensitivity to nadifloxacin or other fluoroquinolones.
Adverse Reactions
Skin and subcutaneous tissue disorders: Itching and erythema at application sites, pruritus, redness, flushing, feeling of facial warmth, papules, contact dermatitis, dry skin.
Description: Nadifloxacin, a synthetic fluoroquinolone anti-infective agent, acts by inhibiting the bacterial DNA gyrase which is involved in DNA synthesis and replication, thus inhibiting bacterial multiplication
Absorption: Time to peak plasma concentration: 8 hours (post-final dosing).
Excretion: Via urine (approx 0.09%). Elimination half-life: 19.4 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Nadifloxacin, CID=4410, (accessed on Mar. 25, 2020)

Store below 30°C.
MIMS Class
Topical Antibiotics
ATC Classification
D10AF05 - nadifloxacin ; Belongs to the class of topical antiinfective preparations used in the treatment of acne.
Acuatim (Otsuka). MIMS Indonesia. Accessed 17/01/2020.

Anon. Nadifloxacin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/01/2020.

Buckingham R (ed). Nadifloxacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/01/2020.

Nadibact (Cipla - Xterna). MIMS Philippines. Accessed 17/01/2020.

Quinolones. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. Accessed 17/01/2020.

Disclaimer: This information is independently developed by MIMS based on Nadifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in